INTRODUCTION
Erythrocyte groups were first implicated in human transplantation in 1919 by Shawan' s report that the use of blood grouping principles in skin grafting could result in prolonged allograft survival (1) . The exact role of such antigens in conditioning allograft responses has, however, remained obscure A partial report of this work was read at the 53rd Annual Clinical Congress of the American College of Surgeons, 2 October 1967.
Received for publication 5 February 1968 and in revised form 9 May 1968. for some years (2) . The studies of Brown and McDowell (3) and of Woodruff and Allan (4) appeared to indicate that blood groups were of no particular significance in conditioning the rejection of skin allografts in man. In addition, Medawar (5, 6) provided cogent evidence that erythrocytes were not active as individual-or strain-specific transplantation antigens in experimental animals. In a different experimental setting, however, Barrett and Hansen (7) showed that erythrocyte stromata could sensitize mice to tumor transplants. More recently, Griffiths and Crikelair (8) and Kuhns, Rapaport, Lawrence, and Converse (9) described anti-A and/or anti-B antibody responses in human recipients of transplantation antigens (skin graft, leukocyte extracts) obtained from ABO-incompatible donors, once again implicating erythrocyte antigens in experimental allograft responses.
The possibility that erythrocyte antigens might also be of importance in organ transplantation was initially noted by Simonsen and Sorensen and transplant obtained from a group B donor. This transplant ceased to function on the 7th postoperative day, and, although other variables were also implicated, the authors concluded that renal transplantation would be unwise in the face of major blood group incompatibilities. This observation has influenced Hume et al.'s selection of donors and recipients for renal transplantation since that time (14) (15) (16) (17) . Woodruff (18) , Hamburger, Vaysse, Crosnier, Aubert, and Dormont (19) , Goodwin, Mims, and Kaufman (20) , and Murray and Harrison (21) have also expressed support for the concept that renal allografts should not be performed across major ABO blood group incompatibility barriers. It was not, however, until the carefully documented clinical studies of Starzl et al. (22) (23) (24) (25) that the influence of ABO group incompatibility upon the fate of human renal allografts became fully established. Kidneys transplanted across major ABO group barriers were shown to risk a particularly rapid and violent type of rejection, whose tempo and intensity were related to a significant extent to pretransplantation anti-A or anti-B isoantibody titers in the recipients (26) . A recent report of the Kidney Transplant Registry fully confirms this concept (27) , and the observations of Jacobson and Najarian (28) that pretreatment of dogs with serologically incompatible erythrocytes may induce in the recipients a decrease in survival times of kidney transplants obtained from donors of the same erythrocyte group suggests that some form of isosensitization may have been implicated in the mediation of such responses.
It is the purpose of this study to assess the role of erythrocyte group antigens in human transplantation under experimental conditions designed to delineate the circumstances under which such antigens might be capable of inducing rapid allograft rejection. In preliminary experiments, blood group 0 recipients immunized with AB erythrocytes were noted to reject skin allografts obtained from other donors belonging to blood group AB in an accelerated manner, whereas grafts obtained from group 0 donors were rejected in first-set fashion (29) . The present report describes responses to 94 ABO blood group-compatible and incompatible skin allografts in 19 recipients pretreated with ABO group-compatible or incompatible erythrocytes, or with water-soluble A, B, and 0 (H) antigens. The results indicate that pretreatment with A or B erythrocyte group antigens in the form of erythrocytes, or as water-soluble substances, induces in blood group 0 recipients a state of hypersensitivity to skin allografts obtained from donors of the same incompatible erythrocyte group (A or B). This sensitivity is expressed in the recipients by the white graft or accelerated rejection of the ABO-incompatible transplants. In contrast, skin grafts obtained from blood group 0 donors and applied to the recipients at the same time are accorded normal first-set survivals. The serum antibody responses observed in the recipients as a result of pretreatment and of subsequent challenge with skin allografts are described, with particular reference to their possible relationship to the types of graft responses observed. (2) Four group A1 recipients were injected with A1 erythrocytes and tested with group 0 and group A1 grafts 2 wk later.
METHODS
(3) Five group 0 recipients were injected intradermally with soluble A or B substances; they were tested 2 wk later with grafts from group 0 donors, and with grafts obtained from group A1 or B donors, respectively. In addition, one group A1 recipient was pretreated with soluble B substance, and was then tested with grafts obtained from group B and group 0 donors. The final recipient in this series was a group A1B subject who was pretreated in similar fashion with 0 (H) substance, and was tested with grafts obtained from donors of blood groups ALB, B, and 0.
Earlier studies of allograft rejection responses in man have indicated that the usual first-set skin allograft survival time is 10-12 days. In this study, as in previous reports, the accelerated (4-5 days) or white graft rejection of skin allografts have been interpreted as a manifestation of hypersensitivity of the host to the individualspecific and/or group-specific antigens present in the donors of such grafts. The white graft reaction has also been considered as an expression of a higher state of sensitivity than that expressed by graft rejection at 4-5 days (30) (31) (32) (33) (34) (35) (36) (37) (38) .
Materials used for pretreatment of recipients. Aliquots of blood were obtained from each donor. They were defibrinated in order to eliminate the blood platelets, and they were then freed of leukocytes by seven or eight successive sedimentations in Dextran (6%o solution, mol wt 200,000). No leukocytes were detectable in the majority of the final erythrocyte suspensions used; occasional lymphocytes were noted in some instances but they never exceeded 3000-4000 cells in each preparation.
Soluble A substance was obtained from commercial sources.' This material, extracted from hog gastric mucosa, was analyzed by Dr. Elvin A. Kabat of Columbia University. It contained 58 gamma/ml of nitrogen; 295 gamma/ml of N-acetyl glucosamine; 136 gamma/ml of galactose, and 94.5 gamma/ml of fucose. Soluble 0 (H) substance extracted from hog gastric mucosa in similar fashion, and containing the same nitrogen concentration was also obtained from Dr. Elvin A. Kabat. This material differs from soluble A substance only by the absence of the amino-sugar determinants present in A substance (39) . Soluble B substance isolated from horse stomach lining was obtained from commercial sources (Knickerbocker Laboratories). Its composition has previously been described in detail by Baer, Kabat, and Knaub (40) .
The final erythrocyte preparations were suspended in pyrogen-free isotonic saline solution, and were injected intradermally in divided doses of 0.1-0.2 ml, into the deltoid region of the shoulders of the recipients. The water-soluble A, B, and 0 (H) substances were injected in similar volumes into the same regions. In those instances where intravenous injections of erythrocyte suspensions were employed, the latter were also resuspended in isotonic saline solution before injection.
Schedule of sensitization of the recipients. (1) Four group 0 recipients were injected with A2B erythrocytes, given in 4 consecutive wk injections of 6.4-9 X 109 cells. The cells were injected intravenously in two recipients and intradermally in the other two individuals. 1 wk after the last injection, each subject received three skin allografts from A1B and A2B donors, and three grafts obtained from group 0 donors. Two other group 0 individuals received intravenous injections of similar amounts of group A1 or of group B erythrocytes, respectively. 1 wk after the last injection, they were also tested with grafts obtained from three group 0 donors, and with grafts obtained from three group A1 or group B donors, respectively.
( secutive wk, and were tested with skin grafts obtained from three group 0 donors and from three group A, donors 1 wk later (i.e., 28 days after the first injection of A substance). A third subject (VAI) received the first two injections of A substance, but developed a massive inflammatory reaction at the injection site, which resulted in a reduction of his last sensitizing dose to 0.3 mg of A substance. The fourth subject (BAR) only received the first two doses of A substance (i.e., 6 mg) for similar reasons. Subjects VAI and BAR were both tested with grafts obtained from three group 0 and three group A1 donors at 28 days after the 1st sensitizing injection.
Comparable amounts of 0 (H) substance were injected into a group A1B recipient, who was tested with three grafts obtained from A1B donors, two grafts obtained from 0 donors, and one graft obtained from a B donor, 28 days after the first injection of 0 (H) substance. Two other recipients were injected in similar fashion with soluble B substance, including one individual of blood group 0 (TIC), and one group A1 recipient (FIL). Both subjects were tested with grafts obtained from three group 0 donors, and with grafts obtained from three group B donors, 28 days after the 1 st injection of B substance.
Methods of grafting and of graft observation
The methods of grafting and of graft observation have been described in detail in previous publications (30, 32, 34, 41) . All grafts were full-thickness skin specimens measuring 11 mm in diameter, placed on the anterior surface of the forearms of the recipients. The transplants were observed daily; gross and stereomicroscopic criteria were employed for the diagnosis of graft rejection. Such criteria included cessation of blood flow and thrombosis in the superficial graft vessels, graft cyanosis, and edema, and the development of erythema and induration around the grafts (41) . In the case of the white graft reaction, the absence of vascularization, dead white color of the grafts, and their evolution into a tan-colored eschar, provided the landmarks for recognition of this type of response (32) .
Serologic Studies. Serum samples were obtained from the recipients before pretreatment, and at weekly intervals thereafter, until the 4th wk after graft rejection. The sera were preserved at -22°C, and were inactivated at 56°C for 30 min before use. Each aliquot was tested for its anti-A and anti-B hemagglutinin titers by standard hemagglutination tests, utilizing 1% suspensions of hu-man blood group A and B erythrocytes. The hemagglutinin titers are presented in the tables and text as reciprocals of the highest serum dilution at which definite agglutination occurred. Parallel hemolysin titer determinations were also performed by standard techniques.
Selected serum samples were diluted to 1: 4 and were incubated for 1 hr at 370C with equal volumes of 0.2 M 2-mercaptoethanol; they were then used immediately in hemagglutination tests (42) . The immunoglobulin properties of high-titered antisera were also studied by sucrose density gradient ultracentrifugation (43) . A volume of 0.5 ml of selected serum samples, at a dilution corresponding to 32-64 agglutinating U, was layered over a sucrose density gradient (10-40%). Separation was performed in a swinging bucket rotor (Spinco ultracentrifuge) at 95,000 g for 16 hr. Successive fractions were obtained by the drop collection method, and were examined by hemagglutination tests against group A and B erythrocytes after dialysis against saline.
RESULTS
(1) Pretreatment of group 0 recipients with ABO-incompatible erythrocytes. As noted in Table I , 18 skin allografts obtained from blood group 0 donors were accorded first-set survival times (6-13 days) in recipients pretreated with A2B, A1, or B erythrocytes. Skin grafts from group AB (A1B or A2B) donors were rejected in the same subjects as first-set grafts (6-8 days) in five instances, and in an accelerated manner (4) (5) S white graft reaction. 21 38
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The final recipient was a group A1B individual (COL) pretreated with 0 (H) substance. This subject rejected three grafts from A1B donors, one graft from a group B donor, and two grafts from group 0 donors as first-set grafts (7-11.5 days).
(4) Isoagglutinin titers in recipients of blood group antigens and skin allografts. Fig. 1 illustrates isoagglutinin titers observed in group 0 recipients pretreated with A1 and B erythrocytes and tested with group 0, A1 or B skin allografts.
None of the recipients developed any significant levels of anti-A or anti-B isoantibody. Pretreatment of group 0 recipients with soluble A substance, however, resulted in significant elevations in anti-A antibody titers (44) . As noted in Fig. 2 , two subjects received 4 consecutive wk 3 mg doses of A substance. The first recipient (JAN) had a preimmunization anti-A titer of 8; this rose to 128 1 wk later, and was 64 at the time of the third injection of A substance. It remained at that level for the remainder of the study. JAN accorded accelerated rejection responses to three grafts obtained from A1 donors. The second subject (HOG) had an anti-A titer of 64 before immunization; this rose to 512 2 wk after the first injection of A substance, and remained at that level while three group A1 skin grafts were rejected as white grafts. Two other group 0 recipients were pretreated with smaller doses of A substance because of the local reactions induced by injection of this material. The presensitization anti-A titer of the first subject (VAI) was 32; it rose to 1024 2 wk later. VAI received only 0.3 mg of A substance on the 21st day; the isoagglutinin titer was 512 at that time, and remained at this level at the time of white graft rejection of three group A, grafts.
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The second recipient (BAR) had a base line anti-A antibody titer of 28; this titer rose to 8192 within 1 wk. At this time, the second injection of A substance also evoked an intense inflammatory reaction, and pretreatment was discontinued. This subject's anti-A titer remained 8192 during the next 2 wk, and reached 32,778 at the time of white graft rejection of three skin transplants obtained from group A, donors. Moderate increases in anti-B antibody titers occurred in parallel with the anti-A responses described.
The isoagglutinin responses observed in recipients of B substance are illustrated in Fig. 3 . Subject TIC (blood group 0) whose base line anti-B antibody titer was 32, received 9 mg of B substance. The titer rose to 512 2 wk after the first injection of B substance, and was 1024 at the time of skin grafting. Three The ability of soluble antigens isolated from hog (A substance) and horse (B substance) stomachs to induce allograft sensitivity in man broadens the range of heterologous antigens implicated in the induction of mammalian transplantation responses. In this regard, the results may be pertinent to Brent, Medawar, and Ruszkiewicz's description of serologic cross-reactions between soluble A substance, pneumococcal polysaccharide, and the H-2 antigens of the mouse (46) , and to the observation that group A streptococci and staphylococci can induce strong allograft sensitivity in rodents (47) (48) (49) (50) (51) . The results are also in harmony with the recent detection of heterophile hemagglutinins directed against sheep, guinea pig, and rat erythrocytes in recipients of human transplantation antigens (52) .
The mechanisms responsible for the accelerated and/or white graft rejection of grafts obtained from group A, B, or AB donors in group 0 recipients of the corresponding incompatible erythrocyte group antigens are not clear at this time. Humoral agents would appear to be implicated by the apparent relationship between serum isoagglutinin levels and the incidence of white graft responses in recipients of soluble blood group substances, This interpretation is consonant with Wilson and Kirkpatrick's observation of a similar relationship between preformed anti-A and/or anti-B antibody titers in the host and the rapid rejection of ABO-incompatible renal allografts (26) . It would also provide a possible explanation for the occasional white graft responses described in group 0 recipients of skin allografts obtained from group A donors in the absence of any obvious pretreatment (53) . Indeed, the presence of blood group A substance in commercial peptones (39) has introduced this antigen as a contaminant in bacterial vaccines, toxoids, and other materials administered parenterally to human recipients. Such treatment may result in the development of significant antibody responses in individuals lacking this antigen (54) , and may be related to the recipient's subsequent response to tissue transplants obtained from group A donors.
Involvement of cellular effector mechanisms in the allograft responses described in this report is suggested, however, by the absence of detectable serum isoantibody levels in some pretreated recipients who rejected blood group-incompatible grafts in an accelerated and/or white graft fashion. The possible role of cellular factors in this regard is also strengthened by the demonstration that leukocyte extracts obtained from specifically sensitized donors are capable of mediating individual-specific skin allograft rejection (accelerated rejection) in man (55) .
It is possible, however, that the mechanisms of graft rejection operative under the present experimental conditions are not related to any of the types of allograft responses described previously. A definitive conclusion on these possibilities awaits the biological testing of the cellular and/or humoral factors associated with this type of response. The relative capacity of such factors to transfer ABO erythrocyte group-specific skin allograft sensitivity to normal recipients is currently under investigation. 
ADDENDUM
